Sastasundar Ventures Ltd Q1FY26 FY25 – Healthcare ka Amazon + Finance ka Lassi Shop, but Net Profit still doing Yoga?
1. At a Glance
Welcome to the circus of Sastasundar Ventures Ltd (SSVL) — market cap just ₹999 crore, which in today’s market is the price of one overpriced Gurugram apartment with a “garden view.” The stock is chilling at ₹314, giving an 8.9% return in the last 3 months. Not bad, but still less exciting than the returns you get from your local chit fund. PE ratio sits at 27.8 (industry median 38), which basically says “I’m expensive, but not as expensive as my cousins in diagnostics.” ROE is 4.6% — a number so tiny it could be written in invisible ink. ROCE? Negative, because why not. Sales are ₹1,139 crore, PAT is a meh ₹35.9 crore, and Operating Margin is sitting at -4.1%, meaning every rupee earned is immediately running away to expenses faster than you run when someone asks “Beta shaadi kab karoge?”
2. Introduction
If there’s ever a Netflix show called Healthcare Meets Finance Meets Bollywood Drama, Sastasundar Ventures would be the pilot episode. Born in 1989, this company has been everything from a core investment firm to a wannabe Flipkart partner to a diagnostic center. Basically, they’ve tried more business models than you’ve tried diets.
First, they went digital pharmacy with SastaSundar.com, then got Flipkart Health to take over the heavy lifting. Then they added diagnostics with Genu Path Labs because why not. And when boredom struck, they sprinkled in financial services — loans, securities, consultancy — basically everything except selling samosas.
Their revenue mix screams “Healthcare heavy” (94%), while financial services sulk at 6%. But here’s the kicker — despite being “almost debt-free” (less than ₹1 crore borrowings), they still manage to post negative operating margins. Imagine being debt-free and still broke — truly inspirational.
And just when you thought things were stable, news comes in: frauds in subsidiaries (yes, plural), SEBI rejecting their scheme of arrangement, CFO resignations like musical chairs, and the latest spicy masala — a ₹600 crore related party transaction. Bollywood scriptwriters, are you watching?
3. Business Model – WTF Do They Even Do?
Let’s break it down for the lazy smart investor:
Financial Services → Basically a Core Investment Company (CIC). They finance loans, play with securities, give consultancy, wealth management, and probably free gyaan no one asked for. Contribution to revenue? A sad 6%.
Healthcare Network → The real deal. Subsidiaries run B2C, B2B, and diagnostics.
B2C – SastaSundar.com: Used to be a healthcare e-commerce platform. Then Flipkart waltzed in, rebranded it to Flipkart Health+, and Sastasundar became a sidekick with a 24.9% stake. Spoiler alert: In October 2024, they sold their entire stake to Flipkart Health Singapore. Exit ho gaya.
B2B – RetailerShakti: Supplies medicines, wellness products, FMCG to retail chemists and kiranas. Think of it as the BigBasket for chemists.
Diagnostics – Genu Path Labs: A small but growing diagnostic business in Eastern India. Not exactly Dr. Lal Pathlabs, but hey, at least they try.
So, in short: They’re a wannabe conglomerate juggling pharmacy, B2B supply, diagnostics, and finance. If Reliance is Ambani’s thali, Sastasundar is a college canteen buffet — too many items, half-baked taste.
